SCHEMBL30014786

SCHEMBL30014786

CCc1cc(Nc2ncc(Br)c(Nc3ccc4c(c3N(C)S(C)(=O)=O)OCCO4)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 20/20 0.69
▸ MET P08581 2/20 0.56
▸ CHEK1 O14757 1/20 0.56
▸ AURKA O14965 1/20 0.56
▸ CCNT1 O60563 1/20 0.56
▸ JAK2 O60674 1/20 0.56
▸ RET P07949 1/20 0.56
▸ ROS1 P08922 1/20 0.56
▸ PDGFRB P09619 1/20 0.56
▸ KIT P10721 1/20 0.56
▸ PIM1 P11309 1/20 0.56
▸ PDGFRA P16234 1/20 0.56
▸ FER P16591 1/20 0.56
▸ EPHA1 P21709 1/20 0.56
▸ MAPK3 P27361 1/20 0.56
▸ EPHB2 P29323 1/20 0.56
▸ AXL P30530 1/20 0.56
▸ MAPK8 P45983 1/20 0.56
▸ CDK9 P50750 1/20 0.56
▸ PKD1 P98161 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24992455 1.00 EGFR (0.69) EGFRMETCHEK1AURKACCNT1
SCHEMBL24993061 0.95 EGFR (0.69) EGFRMETCHEK1AURKACCNT1
SCHEMBL24993175 0.94 EGFR (0.61) EGFRMETCHEK1AURKACCNT1
SCHEMBL24993174 0.94 EGFR (0.61) EGFRMETCHEK1AURKACCNT1
SCHEMBL24993064 0.93 EGFR (0.67) EGFRMETCHEK1AURKACCNT1
SCHEMBL24993148 0.93 EGFR (0.61) EGFRMETCHEK1AURKAJAK2
SCHEMBL24992307 0.92 EGFR (0.58) EGFRMETCHEK1AURKACCNT1
SCHEMBL29173191 0.91 EGFR (0.70) EGFRMETCHEK1AURKACCNT1
SCHEMBL24992476 0.91 EGFR (0.57) EGFRMETCHEK1AURKACCNT1
SCHEMBL24992447 0.91 EGFR (0.69) EGFRMETCHEK1AURKACCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297194-B2 N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof Bridge Biotherapeutics, Inc. (KR) 2025-05-13 — — US disclosed
US-20220332711-A1 N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF Bridge Biotherapeutics, Inc. (KR) 2022-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12297194-B2 N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof EGFR, ERBB2, ERBB4 EGFR 1/4885MET 299/4885CHEK1 343/4885
US-20220332711-A1 N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF EGFR, ERBB2, ERBB4 EGFR 1/4885MET 299/4885CHEK1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback